Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Total Valuation
Larimar Therapeutics has a market cap or net worth of $497.60M. The enterprise value is $328.57M.
Market Cap$497.60M
Enterprise Value$328.57M
Share Statistics
Larimar Therapeutics has 103,882,935 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,882,935
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Larimar Therapeutics’s return on equity (ROE) is -2.12 and return on invested capital (ROIC) is -209.97%.
Return on Equity (ROE)-2.12
Return on Assets (ROA)-1.14
Return on Invested Capital (ROIC)-209.97%
Return on Capital Employed (ROCE)-2.13
Revenue Per Employee0.00
Profits Per Employee-2.55M
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Larimar Therapeutics is ―. Larimar Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio3.56
Price to Fair Value3.56
Price to FCF-2.45
Price to Operating Cash Flow-3.60
PEG Ratio-0.02
Income Statement
In the last 12 months, Larimar Therapeutics had revenue of 0.00 and earned -165.67M in profits. Earnings per share was -2.27.
Revenue0.00
Gross Profit-350.00K
Operating Income-172.50M
Pretax Income-165.67M
Net Income-165.67M
EBITDA-172.50M
Earnings Per Share (EPS)-2.27
Cash Flow
In the last 12 months, operating cash flow was -113.20M and capital expenditures -91.00K, giving a free cash flow of -113.29M billion.
Operating Cash Flow-113.20M
Free Cash Flow-113.29M
Free Cash Flow per Share-1.09
Dividends & Yields
Larimar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.79
52-Week Price Change156.15%
50-Day Moving Average4.20
200-Day Moving Average3.84
Relative Strength Index (RSI)54.43
Average Volume (3m)7.47M
Important Dates
Larimar Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Larimar Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 5.21%
Current Ratio2.19
Quick Ratio2.19
Debt to Market Cap<0.01
Net Debt to EBITDA0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Larimar Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Larimar Therapeutics EV to EBITDA ratio is -1.14, with an EV/FCF ratio of -1.74.
EV to Sales0.00
EV to EBITDA-1.14
EV to Free Cash Flow-1.74
EV to Operating Cash Flow-1.74
Balance Sheet
Larimar Therapeutics has $136.85M in cash and marketable securities with $4.07M in debt, giving a net cash position of $132.78M billion.
Cash & Marketable Securities$136.85M
Total Debt$4.07M
Net Cash$132.78M
Net Cash Per Share$1.28
Tangible Book Value Per Share$1.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Larimar Therapeutics is $13.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.90
Price Target Upside190.19% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast-67.41%